retatrutide weight loss trial results just delivered the first top-line Phase 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Experimental drug Retatrutide shows promising

In the current study, we report DPP4 was elevated 4-fold in Pemt / mice, which have both hepatomegaly and nonalcoholic steatohepatitis (54), demonstrating that in addition to obesity, liver-specific insults can induce the release of DPP4

Directions: Pour the recommended serving into your mouth

ANDREW HUBERMAN: Mechanistic logic

Toxicol Rep

[DOI] [PMC free article] [PubMed] [Google Scholar] 27.Ahren B

Hims & Hers said in a statement in its third-quarter financial results that "discussions are ongoing, no definitive agreement has been executed with Novo Nordisk, and there is a possibility that no definitive agreement may ever be executed with Novo Nordisk." Back in June, the drugmaker abruptly ended a monthlong collaboration with Hims & Hers to make its weight loss drug Wegovy available on the telehealth company's platform